284 related articles for article (PubMed ID: 15623610)
1. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
2. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
[TBL] [Abstract][Full Text] [Related]
3. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
Mohsin SK; Allred DC; Osborne CK; Cruz A; Otto P; Chew H; Clark GM; Elledge RM
Breast Cancer Res Treat; 2005 Dec; 94(3):205-11. PubMed ID: 16267611
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Stearns V; Singh B; Tsangaris T; Crawford JG; Novielli A; Ellis MJ; Isaacs C; Pennanen M; Tibery C; Farhad A; Slack R; Hayes DF
Clin Cancer Res; 2003 Jan; 9(1):124-33. PubMed ID: 12538460
[TBL] [Abstract][Full Text] [Related]
5. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
Lehman CD; Blume JD; Weatherall P; Thickman D; Hylton N; Warner E; Pisano E; Schnitt SJ; Gatsonis C; Schnall M; DeAngelis GA; Stomper P; Rosen EL; O'Loughlin M; Harms S; Bluemke DA;
Cancer; 2005 May; 103(9):1898-905. PubMed ID: 15800894
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
7. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials.
Fabian CJ; Zalles C; Kamel S; Zeiger S; Simon C; Kimler BF
J Cell Biochem Suppl; 1997; 28-29():101-10. PubMed ID: 9589354
[TBL] [Abstract][Full Text] [Related]
8. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
9. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.
Fabian CJ; Kamel S; Zalles C; Kimler BF
J Cell Biochem Suppl; 1996; 25():112-22. PubMed ID: 9027607
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
11. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.
Port ER; Park A; Borgen PI; Morris E; Montgomery LL
Ann Surg Oncol; 2007 Mar; 14(3):1051-7. PubMed ID: 17206485
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials with retinoids for breast cancer chemoprevention.
Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
[TBL] [Abstract][Full Text] [Related]
13. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
14. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
15. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Frank DH; Kimler BF; Fabian CJ; Ranger-Moore J; Yozwiak M; Bartels HG; Alberts DS; Bartels PH
Breast Cancer Res Treat; 2009 Jun; 115(3):661-8. PubMed ID: 19125322
[TBL] [Abstract][Full Text] [Related]
16. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials.
Arun B; Valero V; Logan C; Broglio K; Rivera E; Brewster A; Yin G; Green M; Kuerer H; Gong Y; Browne D; Hortobagyi GN; Sneige N
Clin Cancer Res; 2007 Aug; 13(16):4943-8. PubMed ID: 17699874
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
19. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
20. The Breast Cancer Continuum: insights from the tamoxifen trials impact future drug development strategies.
Lewis JP
Ann N Y Acad Sci; 2001 Dec; 949():327-32. PubMed ID: 11795371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
